Back to Research
Program for Clinical Research in Dermatology
The Program for Clinical Research in Dermatology (PCRiD) provides clinical research opportunities for patients seeking new treatment options, and for healthy volunteers seeking to advance medical discovery.
For More Information
Program Overview
Our team of physicians and researchers are committed to advancing knowledge and understanding of dermatologic conditions and treatments. We conduct all phases (I-IV) of clinical and therapeutic research trials for pharmaceutical companies and is engaged in research studies supported by the National Institutes of Health and other programs. Our researchers work together seamlessly to help translate laboratory findings into new dermatologic therapies.
For more information about PCRiD and ongoing clinical trials, please contact us at (734) 232-0562.
Current Areas of Study
| Principal Investigator | Study Title | Study Website | Enrolling? |
| Johann Gudjonsson | Screening for Conditions by Electronic Nose Technology (SCENT) | https://umhealthresearch.org/studies/HUM00226084 | Yes |
| Principal Investigator | Study Title | Study Website | Enrolling? |
| Yolanda Helfrich | Evaluating Effects of Hijab on Hair and Scalp Health Related Factors | https://umhealthresearch.org/studies/HUM00236102 | Yes |
| Mio Nakamura | A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris | Not available yet | Yes |
| Principal Investigator | Study Title | Study Website | Enrolling? |
| Yolanda Helfrich | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | https://clinicaltrials.gov/study/NCT03989206 | No |
| Johann Gudjonsson | Moderate-to-Severe Hidradenitis Suppurativa and Atopic Dermatitis: Open-Label interventional Biomarker Study of Lutikizumab in Adult Subjects | https://umhealthresearch.org/studies/HUM00256922 | Yes |
| Johann Gudjonsson | Ethnic Differences in Mechanism of Action to Dupilumab | https://umhealthresearch.org/studies/HUM00201405 | Yes |
| Johann Gudjonsson | A Phase IV, Non-Randomized, Open-Label Multinational Trial to Assess the Mechanism of Action For Lebrikizumab in Moderate-to-Severe Atopic Dermatitis | https://umhealthresearch.org/studies/HUM00272032 | Yes |
| Johann Gudjonsson | Screening for Conditions by Electronic Nose Technology (SCENT) | https://umhealthresearch.org/studies/HUM00226084 | Yes |
| Chase Schuler | Michigan Food and Atopic Dermatitis (“M-FAD”) Program – Molecular Analytics Project | https://umhealthresearch.org/studies/HUM00235532 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| J. Michelle Kahlenberg | Personalized Medicine through Integration of Immune Phenotypes in Autoimmune Skin Disease | https://umhealthresearch.org/studies/HUM00151834 | Yes |
| Johann Gudjonsson | Inflammatory Spectrum in Skin Diseases | https://umhealthresearch.org/studies/HUM00174864 | Yes |
| Mio Nakamura | A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy. | https://clinicaltrials.gov/study/NCT06015737 | Yes |
| Mio Nakamura | A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis | https://clinicaltrials.gov/study/NCT07047690 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Allison Billi | Investigating Active Surveillance for Management of Low-Risk Basal Cell Carcinoma in the Elderly | https://clinicaltrials.gov/study/NCT06539468 | Yes |
| Mio Nakamura | A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome | https://clinicaltrials.gov/study/NCT06050122 | No |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | An Exploratory Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics (PK/PD) of Nemolizumab in Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) | https://clinicaltrials.gov/study/NCT07074977 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy. | https://clinicaltrials.gov/study/NCT06015737 | Yes |
| J. Michelle Kahlenberg | Personalized Medicine through Integration of Immune Phenotypes in Autoimmune Skin Disease | https://umhealthresearch.org/studies/HUM00151834 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome | https://clinicaltrials.gov/study/NCT06050122 | No |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa | https://clinicaltrials.gov/study/NCT07007637 | No |
| Johann Gudjonsson | Moderate-to-Severe Hidradenitis Suppurativa and Atopic Dermatitis: Open-Label interventional Biomarker Study of Lutikizumab in Adult Subjects | https://umhealthresearch.org/studies/HUM00256922 | Yes |
| Johann Gudjonsson | Screening for Conditions by Electronic Nose Technology (SCENT) | https://umhealthresearch.org/studies/HUM00226084 | Yes |
| Johann Gudjonsson | Inflammatory Spectrum in Skin Diseases | https://umhealthresearch.org/studies/HUM00174864 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Alex Tsoi | Multi-omic study of immune-mediated skin diseases and their comorbidities | N/A | No |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris | Not available yet | Yes |
| Principal Investigator | Study Title | Study Website | Enrolling? |
| Yolanda Helfrich | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis | https://clinicaltrials.gov/study/NCT04204616 | No |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | Phototherapy in Psoriasis Patients of Skin of Color | https://umhealthresearch.org/studies/HUM00253933 | Yes |
| Michael Goldfarb | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | https://clinicaltrials.gov/study/NCT06220604 | No |
| Michael Goldfarb | A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis | https://clinicaltrials.gov/study/NCT06550076 | No |
| Johann Gudjonsson | A Phase 3B Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants with Moderate to Severe Plaque Psoriasis | https://umhealthresearch.org/studies/HUM00259606 | Yes |
| Johann Gudjonsson | Screening for Conditions by Electronic Nose Technology (SCENT) | https://umhealthresearch.org/studies/HUM00226084 | Yes |
| Johann Gudjonsson | Inflammatory Spectrum in Skin Diseases | https://umhealthresearch.org/studies/HUM00174864 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy | https://clinicaltrials.gov/study/NCT06624670 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Sunny Wong | Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia | https://clinicaltrials.gov/study/NCT06840470 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer Risk | N/A | No |
| Yolanda Helfrich | Biomarkers of Response in Patients Prescribed Acitretin for Prevention of Non-Melanoma Skin Cancers | N/A | Yes |
| Allison Billi | Investigating Active Surveillance for Management of Low-Risk Basal Cell Carcinoma in the Elderly | https://clinicaltrials.gov/study/NCT06539468 | Yes |
| Mio Nakamura | A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome | https://clinicaltrials.gov/study/NCT06050122 | No |
| Principal Investigator | Study Title | Study Website | Enrolling? |
| Johann Gudjonsson | Inflammatory Spectrum in Skin Diseases | https://umhealthresearch.org/studies/HUM00174864 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Mio Nakamura | A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis | https://clinicaltrials.gov/study/NCT07047690 | Yes |
| Principal Investigator | Study Title | Website | Enrolling? |
| Michael Goldfarb | A Phase 3 Randomized Withdrawal And Dose-Up Titration, Multicenter Extension Study Investigating The Safety, Efficacy, And Tolerability Of Ritlecitinib In Adult And Adolescent Participants With Nonsegmental Vitiligo | https://clinicaltrials.gov/study/NCT05583526 | No |
U-M Health Research Studies
Learn more about research studies at the University of Michigan.
Additional Resources
Clinical Trials and Studies
Search for more information about active clinical trials and studies in the National Library of Medicine.
Leadership
Mio Nakamura, MD, MS
Clinical Assistant Professor of Dermatology
Associate Medical Director and Program Director
Dermatology
Medical School
Associate Medical Director and Program Director
Dermatology
Medical School
Nicole Mahn, MHA, CCRP
PCRiD Manager
